Dupuytren??s disease

Abstract

Purpose of review: Recent research continues to delineate the pathogenesis of Dupuytren's disease at the cellular and molecular level while exploring the clinical relevance of new findings. The following review is intended to provide the clinician with an update about the pathogenesis of Dupuytren's disease and the significance and potential clinical uses of additional treatment options. Recent findings: New mediators at the cellular level have been reported in the literature that affects the pathogenesis of Dupuytren's disease. Unique gene mutations have also been detailed. Nonsurgical modalities that have been recently tested include 5-Fluorouracil injection, clostridial collagenase injection, and hyperbaric oxygen. Summary: Despite the ever-growing detection of new chemical mediators with Dupuytren's disease, their application in the control and progression of the disease is indeterminate and has not changed conventional clinical practice. Surgical fasciectomy remains the accepted treatment of Dupuytren's disease. Other treatment options continue to be investigated but are either in their infancy or show little clinical efficacy.